Trospium

• Cobenfy, a novel schizophrenia treatment targeting M1/M4 muscarinic receptors, has received FDA approval and demonstrates efficacy in reducing both positive and negative symptoms. • A post-hoc analysis of Phase 3 trials using Cambridge Cognition's CANTAB reveals cognitive performance improvements in schizophrenia patients with pre-existing cognitive impairment. • The CANTAB assessment tool proves instrumental in tracking cognitive benefits, enhancing data collection, and accelerating the development of effective schizophrenia treatments. • Cobenfy represents a breakthrough as the first monotherapy to demonstrate replicable cognitive benefits, independent of its impact on positive and negative symptoms.

Xanomeline/trospium chloride (COBENFY™) has received its first approval in the USA for treating schizophrenia in adults, marking a new approach in psychiatric medication.

• Gene therapy has successfully restored hearing in children with hereditary deafness, offering a transformative treatment option. • The first genetically-edited pig kidney transplant into a living human was performed, addressing the critical organ shortage. • Researchers have identified a fundamental cause of lupus, opening potential avenues for reversing the autoimmune disease. • The FDA approved Cobenfy, the first new class of drug in over 30 years for schizophrenia treatment, targeting a novel mechanism.

• Lenacapavir offers a twice-yearly injectable option for HIV prevention, demonstrating high efficacy in trials, particularly benefiting populations with adherence challenges. • Xanomeline-trospium (KarXT) introduces a novel mechanism targeting muscarinic receptors for schizophrenia treatment, reducing symptoms without the common side effects of older antipsychotics. • Tirzepatide shows promise in weight loss and diabetes prevention, with trials indicating significant reductions in diabetes risk and sustained weight management. • Osimertinib extends survival for advanced EGFR-positive non-small cell lung cancer patients, significantly delaying disease progression and reducing brain metastases.

Adams Clinical partners with InSite Clinical Research, expanding its expertise into inpatient psychiatry and schizophrenia clinical trials, marking its entry into Texas.